Reviewing ERYTECH Pharma S.A. (ERYP)’s and NewLink Genetics Corporation (NASDAQ:NLNK)’s results

Both ERYTECH Pharma S.A. (NASDAQ:ERYP) and NewLink Genetics Corporation (NASDAQ:NLNK) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ERYTECH Pharma S.A. N/A 0.00 N/A -2.79 0.00
NewLink Genetics Corporation 12.47M 5.71 53.59M -1.53 0.00

Table 1 highlights ERYTECH Pharma S.A. and NewLink Genetics Corporation’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 shows us the return on equity, net margins and return on assets of both businesses.

Net Margins Return on Equity Return on Assets
ERYTECH Pharma S.A. 0.00% 0% 0%
NewLink Genetics Corporation -429.75% -52.1% -44.2%

Analyst Ratings

In next table is given ERYTECH Pharma S.A. and NewLink Genetics Corporation’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
ERYTECH Pharma S.A. 0 0 0 0.00
NewLink Genetics Corporation 1 1 0 2.50

On the other hand, NewLink Genetics Corporation’s potential upside is 135.60% and its average target price is $4.5.

Institutional and Insider Ownership

ERYTECH Pharma S.A. and NewLink Genetics Corporation has shares owned by institutional investors as follows: 8.16% and 34.8%. Insiders Comparatively, owned 1% of NewLink Genetics Corporation shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ERYTECH Pharma S.A. 2.65% 10.16% 12.47% -20.35% -67.29% 25.93%
NewLink Genetics Corporation 11.04% 21.48% -4.74% -41.42% -74.11% 19.08%

For the past year ERYTECH Pharma S.A. was more bullish than NewLink Genetics Corporation.

ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company’s lead product candidate is Eryaspase, which is in various stages of clinical trails for the treatment of pancreatic cancer, ALL, AML, and solid tumors. It is also developing Erymethionase and Eryminase for the treatment of solid tumors; Eryzyme for the treatment of for rare and specialized conditions; and Erymmune for the treatment of TBD. ERYTECH Pharma Société Anonyme has a research agreement with Fox Chase Cancer Center for the preclinical development of erymethionase for the treatment of homocystinuria; a subcontracting agreement for the production of batches of eryaspase for the company's clinical trials; and a subcontracting framework agreement for the optimization of the manufacturing process of the company’s pharma products. ERYTECH Pharma Société Anonyme was founded in 2004 and is based in Lyon, France.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer. Its portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway. The company is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer (NSCLC); and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors. Its clinical development products include NLG2101 for metastatic breast cancer; NLG2102 for refractory malignant brain tumors; NLG2103 for advanced melanoma; NLG2104 for metastatic pancreatic cancer; NLG2105 for pediatric patients with refractory malignant brain tumors; and NLG2106 for acute myelogenous leukemia. The companyÂ’s HyperAcute cellular immunotherapy product candidates under clinical development include tergenpumatucel-L, is being investigated in Phase Ib/II clinical trial for patients with advanced NSCLC; and dorgenmeltucel-L, is being investigated in a Phase II clinical trial for patients with advanced melanoma. Its infectious disease program includes replication-competent recombinant vesicular stomatitis virus, a vaccine technology to treat Ebola and Marburg viruses. The company has license and collaboration agreements with Genentech, Inc. and Merck, Sharpe and Dohme Corp. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.